儿科扩散中线质瘤H3K27-改变:从发育起源到治疗挑战
Manuela Mandorino1, Ahana Maitra1, Domenico Armenise1
1Research Laboratory for Woman and Child Health, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, 70125 Bari, Italy.
Cancers
|May 25, 2024
概括
扩散性中线结质瘤 (DMG) 是一种儿科脑癌,由影响基因组蛋白基因的H3K27M突变驱动. 这种突变会扰乱大脑发育和干细胞功能,突出显示出需要新的治疗方法.
科学领域:
- 儿科瘤学 儿科瘤学
- 神经瘤学神经瘤学
- 发育神经科学的发展神经科学.
背景情况:
- 扩散内在质质瘤 (DIPG),现在扩散中线质瘤 (DMG),是一种侵袭性的儿科脑癌,没有有效的治疗方法.
- 主要影响4-9岁儿童的DMG,影响深层中线大脑结构,并表明与早期发育中的表观遗传调节的联系.
- 希斯基因中的H3K27M突变是已知的驱动因素,但其在瘤发作和进展中的确切作用尚不清楚.
研究的目的:
- 审查关于扩散中线质瘤 (DMG) 和H3K27M突变的文献.
- 探索H3K27M突变,表观遗传失调和儿科脑瘤发展之间的联系.
- 了解H3K27M对神经前代细胞和大脑发育途径的影响.
主要方法:
- 对DIPG/DMG和H3K27M突变研究的综合文献综述.
- 关于在发育中的大脑中H3基因家族表达的基因组数据的分析.
- 检查H3K27M对细胞增殖和分化等细胞过程的功能影响.
主要成果:
- 超过85%的DMG瘤在基因组蛋白H3.3或H3.1基因中存在H3K27M突变.
- 这种突变导致异常基因表达,促进瘤生长和转移.
- H3K27M影响关键的发育途径,包括上皮 - 介质细胞过渡 (EMT),并破坏干细胞的增殖和分化.
结论:
- H3K27M突变是DMG病变发生的关键因素,影响关键的大脑发育过程.
- 了解DMG的发育起源和表观遗传机制对于开发向疗法至关重要.
- 需要进一步的研究来阐明H3K27M的全部影响,并确定这种破坏性儿科癌症的有效治疗策略.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...